161 related articles for article (PubMed ID: 34946271)
1. Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag.
Autore F; Sora' F; Chiusolo P; Minnella G; Colangelo M; Rossi E; Sica S
Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946271
[TBL] [Abstract][Full Text] [Related]
2. [Development of chronic myelogenous leukemia during treatment with TPO receptor agonist for ITP].
Hattori H; Kuwayama M; Takamori H; Nishiura N; Karasuno T
Rinsho Ketsueki; 2014 Dec; 55(12):2429-32. PubMed ID: 25744045
[TBL] [Abstract][Full Text] [Related]
3. Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia.
Nakamura Y; Itoh Y; Wakimoto N
Int J Hematol; 2023 Apr; 117(4):613-617. PubMed ID: 36374396
[TBL] [Abstract][Full Text] [Related]
4. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
[TBL] [Abstract][Full Text] [Related]
5. Prolonged remission from eltrombopag in chronic refractory idiopathic thrombocytopenic purpura.
Noronha V; Philip SD; Joshi A; Prabhash K
Int J Hematol; 2012 Sep; 96(3):380-2. PubMed ID: 22851056
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
Zhang Y; Kolesar JM
Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
[TBL] [Abstract][Full Text] [Related]
8. [Effectiveness of perioperative administration of eltrombopag in a patient with idiopathic thrombocytopenic purpura undergoing cardiovascular surgery].
Shomura S; Katayama Y; Kusagawa H; Komada T
Kyobu Geka; 2014 Mar; 67(3):203-6. PubMed ID: 24743530
[TBL] [Abstract][Full Text] [Related]
9. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Jarque I; Pérez-Rus G; Pérez-Crespo S; Bernat S; Hernández-Rivas JA; Andrade MM; Cortés M; Gómez-Nuñez M; Olivera P; Martínez-Robles V; Fernández-Rodríguez A; Fuertes-Palacio MA; Fernández-Miñano C; de Cabo E; Fisac R; Aguilar C; Bárez A; Peñarrubia MJ; García-Frade LJ; González-Porras JR
Eur J Haematol; 2016 Sep; 97(3):297-302. PubMed ID: 26709028
[TBL] [Abstract][Full Text] [Related]
10. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
Chouhan JD; Herrington JD
Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
[TBL] [Abstract][Full Text] [Related]
11. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.
Boyers D; Jia X; Jenkinson D; Mowatt G
Pharmacoeconomics; 2012 Jun; 30(6):483-95. PubMed ID: 22480381
[TBL] [Abstract][Full Text] [Related]
12. Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations.
Cook L; Cooper N
Drug Des Devel Ther; 2010 Jul; 4():139-45. PubMed ID: 20689640
[TBL] [Abstract][Full Text] [Related]
13. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
Tarantino MD; Fogarty PF; Shah P; Brainsky A
Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia.
Jolliffe E; Romeril K
Intern Med J; 2014 Jul; 44(7):697-9. PubMed ID: 25041772
[TBL] [Abstract][Full Text] [Related]
15. Successful use of eltrombopag in a child with refractory immune thrombocytopenia: case study and literature review.
Wang XL; Li AM
Blood Coagul Fibrinolysis; 2016 Oct; 27(7):825-827. PubMed ID: 26650460
[TBL] [Abstract][Full Text] [Related]
16. Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.
Lam MS
J Oncol Pharm Pract; 2010 Jun; 16(2):89-103. PubMed ID: 19525300
[TBL] [Abstract][Full Text] [Related]
17. [Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia].
Horikoshi A; Tsukuda J; Abe R; Fujiwara N; Ito E; Takaku T
Rinsho Ketsueki; 2016 May; 57(5):638-41. PubMed ID: 27263792
[TBL] [Abstract][Full Text] [Related]
18. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Pérez-Rus G; Hernández-Rivas JA; Bernat S; Bastida JM; Martínez-Badas MP; Martínez-Robles V; Soto I; Olivera P; Bolaños E; Alonso R; Entrena L; Gómez-Nuñez M; Alonso A; Yera Cobo M; Caparrós I; Tenorio M; Arrieta-Cerdán E; Lopez-Ansoar E; García-Frade J; González-Porras JR
Br J Haematol; 2017 Sep; 178(6):959-970. PubMed ID: 28573819
[TBL] [Abstract][Full Text] [Related]
19. A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience.
Çekdemir D; Güvenç S; Özdemirkıran F; Eser A; Toptaş T; Özkocaman V; Haydaroğlu Şahin H; Ermiş Turak E; Esen R; Cömert M; Sadri S; Aslaner M; Uncu Ulu B; Karakuş A; Selim Bapur D; Alacacıoğlu İ; Aydın D; Tekinalp A; Namdaroğlu S; Ceran F; Tarkun P; Kiper D; Çetiner M; Yenerel M; Demir AM; Yılmaz G; Terzi H; Atilla E; Malkan ÜY; Acar K; Öztürk E; Tombak A; Sunu C; Salim O; Alayvaz N; Sayan Ö; Ozan Ü; Ayer M; Gökgöz Z; Andıç N; Kızılkılıç E; Noyan F; Özen M; Pepedil Tanrıkulu F; Alanoğlu G; Özkan HA; Aslan V; Çetin G; Akyol Erikçi A; Deveci B; Ersoy Dursun F; Dermenci H; Aytan P; Gündüz M; Karakuş V; Özlü C; Demircioğlu S; Akay Yanar OM; Özatlı D; Ündar L; Tiftik EN; Türköz Sucak AG; Haznedaroğlu İ; Özcan M; Şencan M; Tombuloğlu M; Özet G; Bilgir O; Turgut B; Özcan MA; Payzın KB; Sönmez M; Ayyıldız O; Dal MS; Ertop Ş; Turgut M; Soysal T; Kaya E; Ünal A; Pehlivan M; Atagündüz I; Tuğlular Fıratlı T; Saydam G; Diz Küçükkaya R
Turk J Haematol; 2019 Nov; 36(4):230-237. PubMed ID: 31327186
[TBL] [Abstract][Full Text] [Related]
20. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
González-López TJ; Pascual C; Álvarez-Román MT; Fernández-Fuertes F; Sánchez-González B; Caparrós I; Jarque I; Mingot-Castellano ME; Hernández-Rivas JA; Martín-Salces M; Solán L; Beneit P; Jiménez R; Bernat S; Andrade MM; Cortés M; Cortti MJ; Pérez-Crespo S; Gómez-Núñez M; Olivera PE; Pérez-Rus G; Martínez-Robles V; Alonso R; Fernández-Rodríguez A; Arratibel MC; Perera M; Fernández-Miñano C; Fuertes-Palacio MA; Vázquez-Paganini JA; Gutierrez-Jomarrón I; Valcarce I; de Cabo E; Sainz A; Fisac R; Aguilar C; Paz Martínez-Badas M; Peñarrubia MJ; Calbacho M; de Cos C; González-Silva M; Coria E; Alonso A; Casaus A; Luaña A; Galán P; Fernández-Canal C; Garcia-Frade J; González-Porras JR
Am J Hematol; 2015 Mar; 90(3):E40-3. PubMed ID: 25400215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
